HRP20110184T1 - Postupak priprave 5-(haloacetil)-8-(supstituirani oksi)-(1h)-kinolin-2-ona - Google Patents

Postupak priprave 5-(haloacetil)-8-(supstituirani oksi)-(1h)-kinolin-2-ona Download PDF

Info

Publication number
HRP20110184T1
HRP20110184T1 HR20110184T HRP20110184T HRP20110184T1 HR P20110184 T1 HRP20110184 T1 HR P20110184T1 HR 20110184 T HR20110184 T HR 20110184T HR P20110184 T HRP20110184 T HR P20110184T HR P20110184 T1 HRP20110184 T1 HR P20110184T1
Authority
HR
Croatia
Prior art keywords
quinolin
hydroxy
acetyl
substituted oxy
solvent
Prior art date
Application number
HR20110184T
Other languages
English (en)
Inventor
Lohse Olivier
Penn Gerhard
Schilling Hanspeter
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33131902&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20110184(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20110184T1 publication Critical patent/HRP20110184T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/24Oxygen atoms attached in position 8
    • C07D215/26Alcohols; Ethers thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Materials Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Quinoline Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

Abstract

Postupak priprave 5-(α-haloacetil)-8-supstituirani oksi-(1H)-kinolin-2-ona, naznačen time, da obuhvaćaa) reagiranjei) 8-hidroksi-(1H)-kinolin-2-ona s acilatnim agensom i Lewisovom kiselinom da se stvori 5-acetil-8-hidroksi-(1H)-kinolin-2-on; iliii) 8-hidroksi-(1H)-kinolin-2-ona s acilatnim agensom da se stvori 8-acetoksi-(1H)-kinolin-2-on, i obrađivanje, na samom mjestu, 8-acetoksi-(1H)-kinolin-2-ona s Lewisovom kiselinom da se stvori 5-acetil-8-hidroksi-(1H)-kinolin-2-on; b) reagiranje 5-acetil-8-hidroksi-(1H)-kinolin-2-ona pripravljenog u koraku (a) sa spojem formule RL u prisutnosti baze i otapala, da se stvori 5-acetil-8-supstituirani oksi-(1H)-kinolin-2-on, pri čemu R je zaštitna skupina a L je izlazna skupina; ic) reagiranje 5-acetil-8-supstituirani oksi-(1H)-kinolin-2-ona s halogenirajućim agensom u prisutnosti otapala da se stvori 5-(α-haloacetil)-8-supstituirani oksi-(1H)-kinolin-2-on. Patent sadrži još 13 patentnih zahtjeva.

Claims (14)

1. Postupak priprave 5-(α-haloacetil)-8-supstituirani oksi-(1H)-kinolin-2-ona, naznačen time, da obuhvaća a) reagiranje i) 8-hidroksi-(1H)-kinolin-2-ona s acilatnim agensom i Lewisovom kiselinom da se stvori 5-acetil-8-hidroksi-(1H)-kinolin-2-on; ili ii) 8-hidroksi-(1H)-kinolin-2-ona s acilatnim agensom da se stvori 8-acetoksi-(1H)-kinolin-2-on, i obrađivanje, na samom mjestu, 8-acetoksi-(1H)-kinolin-2-ona s Lewisovom kiselinom da se stvori 5-acetil-8-hidroksi-(1H)-kinolin-2-on; b) reagiranje 5-acetil-8-hidroksi-(1H)-kinolin-2-ona pripravljenog u koraku (a) sa spojem formule RL u prisutnosti baze i otapala, da se stvori 5-acetil-8-supstituirani oksi-(1H)-kinolin-2-on, pri čemu R je zaštitna skupina a L je izlazna skupina; i c) reagiranje 5-acetil-8-supstituirani oksi-(1H)-kinolin-2-ona s halogenirajućim agensom u prisutnosti otapala da se stvori 5-(α-haloacetil)-8-supstituirani oksi-(1H)-kinolin-2-on.
2. Postupak prema zahtjevu 1, naznačen time, da je acilatni agens prisutan u količini od 1 molarnog ekvivalenta do 1,5 molarnih ekvivalenata, bazirano na molarnim ekvivalentima od 8-hidroksi-(1H)-kinolin-2-ona.
3. Postupak prema zahtjevu 2, naznačen time, da je acilatni agens anhidrid ili acetil klorid.
4. Postupak prema bilo kojem zahtjevu 1 do 3, naznačen time, da je Lewisova kiselina prisutna u količini od 3 molarna ekvivalenta do 5 molarnih ekvivalenata, bazirano na molarnim ekvivalentima od 8-hidroksi-(1H)-kinolin-2-ona ili na molarnim ekvivalentima od 8-acetoksi-(1H)-kinolin-2-ona.
5. Postupak prema zahtjevu 4, naznačen time, da je Lewisova kiselina borov trifluorid, aluminijev klorid ili titanijev tetraklorid.
6. Postupak prema bilo kojem zahtjevu 1 do 5, naznačen time, da je korak (a) proveden u prisutnosti jednog ionskog spoja, pri čemu je ionski spoj alkalijski halid odabran iz skupine koja se sastoji od natrijevog klorida, natrijevog bromida, litijevog klorida i litijevog bromida, ili je to ionska tekućina odabrana iz skupine koja se sastoji od soli imidazola, soli pirida, soli amonijaka, soli fosfonija i soli sulfonija.
7. Postupak prema bilo kojem zahtjevu 1 do 6, naznačen time, da je spoj formule RL odabran iz skupine koja se sastoji od α-metilbenzil bromida, metil klorida, benzil klorida i benzil bromida.
8. Postupak prema bilo kojem zahtjevu 1 do 7, naznačen time, da 5-acetil-8-supstituirani oksi-(1H)-kinolin-2-on je 5-acetil-8-benziloksi-(1H)-kinolin-2-on.
9. Postupak prema bilo kojem zahtjevu 1 do 8, naznačen time, da je halogenirajući agens odabran iz skupine koja se sastoji od natrij bromata i hidrobromične kiseline, broma, N-bromosukcinimida, N-klorosukcinimida, joda, klora, sulfuril klorida, benziltrimetilamonijdikloro-jodata, bakrenog klorida, piridinijevog tribromida, tetraalkilamonijevog tribromida, jodinovog klorida, klorovodične kiseline i oksidacijskog agensa, te od njihovih kombinacija.
10. Postupak prema zahtjevu 9, naznačen time, da je halogenizirajući agens benziltrimetilamonijdiklorojodat.
11. Postupak prema bilo kojem zahtjevu 1 do 10, naznačen time, da 5-(α-haloacetil)-8-supstituirani oksi-(1H)-kinolin-2-on je 5-(α-kloroacetil)-8-benziloksi-(1H)-kinolin-2-on.
12. Postupak prema bilo kojem zahtjevu 1 do 11, naznačen time, da je u koraku (a) otapalo odabrano iz skupine koja se sastoji od metilenklorida, 1,2-etilen diklorida, klorobenzena, o-dikloro-benzena, alifatskog C6-C12-ugljikovodika i njihovih kombinacija; u koraku (b) otapalo je odabrano iz skupine koja se sastoji od acetona, metil izobutil ketona, tetrahidrofurana, diizopropil etera, 2-metoksietil etera, dietilen etera, metilen klorida, vode i njihovih kombinacija; a u koraku (c) otapalo je odabrano iz skupine koja se sastoji od octene kiseline, trifluorooctene kiseline, propionske kiseline, etil acetata, izopropil acetata, butil acetata, toluena, benzena, tetrahidrofurana, diizopropil etera, 2-metoksietil etera, dietilen etera, metilen klorida i njihovih kombinacija.
13. Postupak prema bilo kojem zahtjevu 1 do 12, naznačen time, da u koraku (a) je temperatura od 0°C do 160°C; u koraku (b) temperatura je od 20°C do 90°C; a u koraku (c) temperatura je od 10°C do 160°C.
14. Postupak priprave soli od 5-[(R)-2-(5,6-dietil-indan-2-ilamino)-1-hidroksi-etil]-8-hidroksi-(1H)-kinolinon-2-ona, naznačen time, da obuhvaća: (a) reagiranje (i) 8-hidroksi-(1H)-kinolin-2-ona s acilatnim agensom i Lewisovom kiselinom da se stvori 5-acetil-8-hidroksi-(1H)-kinolin-2-on; ili (ii) 8-hidroksi-(1H)-kinolin-2-ona s acilatnim agensom da se stvori 8-acetoksi-(1H)-kinolin-2-on, i obrađivanje, na samom mjestu, 8-acetoksi-(1H)-kinolin-2-ona s Lewisovom kiselinom da se stvori 5-acetil-8-hidroksi-(1H)-kinolin-2-on; (b) reagiranje 5-acetil-8-hidroksi-(1H)-kinolin-2-ona pripravljenog u koraku (i) sa spojem formule RL u prisutnosti baze i otapala da se stvori 5-acetil-8-supstituirani oksi-(1H)-kinolin-2-on, pri čemu R je zaštitna skupina, a L je izlazna skupina; (c) reagiranje 5-acetil-8-supstituirani oksi-(1H)-kinolin-2-ona sa halogenirajućim agensom u prisutnosti otapala da se stvori 5-(α-haloacetil)-8-supstituirani oksi-(1H)-kinolin-2-on; (d) reagiranje 5-(α-haloacetil)-8-supstituirani oksi-(1H)-kinolin-2-ona s redukcijskim sredstvom u prisutnosti kiralnog katalizatora da se stvori 8-(supstituirani oksi)-5-((R)-2-halo-1-hidroksi-etil)-(1H)-kinolin-2-on; (e) obrađivanje 8-(supstituirani oksi)-5-((R)-2-halo-1-hidroksi-etil)-(1H)-kinolin-2-ona s bazom u prisutnosti otapala da se stvori 8-(supstituirani oksi)-5-(R)-oksiranil-(1H)-kinolin-2-on; (f) reagiranje 8-supstituirani oksi-5-(R)-oksiranil-(1H)-kinolin-2-ona koji ima formulu (I) [image] s 2-amino-(5-6-dietil)-indanom da se stvori reakcijska smjesa koja sadrži spojeve s formulama (II), (III) i (IV) [image] [image] gdje R je zaštitna skupina; (g) obrađivanje reakcijske smjese pripravljene u koraku (f) s kiselinom u prisutnosti otapala da se stvori odgovarajuća sol; (h) izoliranje i kristalizacija soli koja ima formulu (V) [image] gdje R je zaštitna skupina a A- je anion; (i) uklanjanje zaštitne skupine iz soli koja ima formulu (V) u prisutnosti otapala da se dobije sol koja ima formulu (VI): [image] gdje A- je anion; i (j) obrađivanje soli formule (VI) s kiselinom u prisutnosti otapala da se stvori sol od 5-[(R)-2-(5,6-dietil-indan-2-ilamino)-1-hidroksi-etil]-8-hidroksi-(1H)-kinolin-2-ona koja ima formulu (VII) [image] gdje X- je anion.
HR20110184T 2003-04-02 2011-03-14 Postupak priprave 5-(haloacetil)-8-(supstituirani oksi)-(1h)-kinolin-2-ona HRP20110184T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45972403P 2003-04-02 2003-04-02
PCT/EP2004/003479 WO2004087668A1 (en) 2003-04-02 2004-04-01 A process for the preparation of 5-(haloacetyl)-8-(substituted oxy)-(1h)-quinolin-2-ones

Publications (1)

Publication Number Publication Date
HRP20110184T1 true HRP20110184T1 (hr) 2011-04-30

Family

ID=33131902

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110184T HRP20110184T1 (hr) 2003-04-02 2011-03-14 Postupak priprave 5-(haloacetil)-8-(supstituirani oksi)-(1h)-kinolin-2-ona

Country Status (35)

Country Link
US (1) US7605267B2 (hr)
EP (1) EP1613599B8 (hr)
JP (1) JP4726778B2 (hr)
KR (1) KR101073740B1 (hr)
CN (1) CN1774423A (hr)
AR (2) AR043825A1 (hr)
AT (1) ATE491690T1 (hr)
AU (1) AU2004226212B2 (hr)
BR (1) BRPI0409154B1 (hr)
CA (1) CA2520990C (hr)
CL (1) CL2004000706A1 (hr)
CO (1) CO5700779A2 (hr)
CY (1) CY1111515T1 (hr)
DE (1) DE602004030553D1 (hr)
DK (1) DK1613599T3 (hr)
EC (1) ECSP056059A (hr)
ES (1) ES2358193T3 (hr)
HK (1) HK1086833A1 (hr)
HR (1) HRP20110184T1 (hr)
IL (1) IL171053A (hr)
IS (1) IS2800B (hr)
MA (1) MA27761A1 (hr)
MX (1) MXPA05010616A (hr)
MY (1) MY141871A (hr)
NO (1) NO331980B1 (hr)
NZ (1) NZ542623A (hr)
PE (2) PE20050211A1 (hr)
PL (1) PL1613599T3 (hr)
PT (1) PT1613599E (hr)
RU (1) RU2339621C2 (hr)
SI (1) SI1613599T1 (hr)
TN (1) TNSN05245A1 (hr)
TW (1) TWI324151B (hr)
WO (1) WO2004087668A1 (hr)
ZA (1) ZA200507603B (hr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GB0413960D0 (en) * 2004-06-22 2004-07-28 Novartis Ag Organic compounds
EP2044025B1 (en) 2006-06-30 2012-10-03 Novartis AG Quinolinone derivatives and their pharmaceutical compositions
WO2013132514A2 (en) * 2012-03-09 2013-09-12 Rao Davuluri Ramamohan A novel process for the preparation of (r)-5-[2-[(5, 6-diethyl-2, 3-dihydro-1h-inden-2-yl) amino]-1-hydroxyethyl]-8-hydroxy quinolin-2(1h)-one
CN102633717B (zh) * 2012-03-30 2013-11-20 西南大学 N-乙酰-喹啉-2(1h)酮类化合物及其制备方法和应用
CN104379566B (zh) * 2012-07-11 2016-08-24 上海威智医药科技有限公司 茚达特罗中间体及茚达特罗的合成方法
CZ306252B6 (cs) 2013-03-15 2016-10-26 Zentiva, K.S. Způsob přípravy 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H)-chinolin-2-onu (indacaterolu)
WO2015104718A2 (en) 2014-01-09 2015-07-16 Davuluri, Ramamohan Rao A novel process for preparation of indacaterol or its pharmaceutically acceptable salts
CN105693603B (zh) * 2014-11-24 2019-11-29 上海医药工业研究院 改良的马来酸茚达特罗制备工艺
CN107531636B (zh) * 2015-04-09 2022-11-25 正大天晴药业集团股份有限公司 茚达特罗或其盐的制备方法
CN107868045A (zh) * 2016-09-28 2018-04-03 四川海思科制药有限公司 一种茚达特罗中间体的制备方法
CN108264483A (zh) * 2016-12-31 2018-07-10 天津金耀集团有限公司 一种马来酸茚达特罗的制备方法
CN109721534B (zh) * 2018-09-25 2022-05-20 四川海思科制药有限公司 一种马来酸茚达特罗中间体及其制备方法和用途
CN114751857A (zh) * 2022-04-29 2022-07-15 梯尔希(南京)药物研发有限公司 一种茚达特罗杂质的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS539228B2 (hr) * 1974-01-31 1978-04-04
CA1164459A (en) 1980-11-11 1984-03-27 Yung-Hsiung Yang Process for preparing (imidazo¬1,2-a|pyridine- 2-yl)-carbostyril or -3,4-dihydrocarbostyryl derivatives
JPS5896022A (ja) * 1981-11-30 1983-06-07 Otsuka Pharmaceut Co Ltd 強心剤
ES519384A0 (es) * 1983-01-28 1984-03-16 Espanola Farma Therapeut Procedimiento para la obtencion de un compuesto derivado de la 2-quinolinona.
ES8605239A1 (es) 1985-12-04 1986-03-16 Astur Pharma Un procedimiento para la preparacion de quinolonas sustitui-das
GB9405019D0 (en) * 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds
WO2003042160A1 (en) * 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
TWI324150B (en) * 2003-02-28 2010-05-01 Novartis Ag Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt

Also Published As

Publication number Publication date
ZA200507603B (en) 2006-11-29
JP4726778B2 (ja) 2011-07-20
NO331980B1 (no) 2012-05-21
TWI324151B (en) 2010-05-01
ATE491690T1 (de) 2011-01-15
CY1111515T1 (el) 2015-08-05
CN1774423A (zh) 2006-05-17
CO5700779A2 (es) 2006-11-30
CL2004000706A1 (es) 2005-01-14
BRPI0409154A (pt) 2006-03-28
KR20050119678A (ko) 2005-12-21
PE20050211A1 (es) 2005-04-27
KR101073740B1 (ko) 2011-10-13
IL171053A (en) 2010-12-30
JP2006522055A (ja) 2006-09-28
TNSN05245A1 (en) 2007-06-11
PT1613599E (pt) 2011-03-17
PE20100399A1 (es) 2010-06-01
AU2004226212A1 (en) 2004-10-14
NO20055099D0 (no) 2005-11-01
WO2004087668A1 (en) 2004-10-14
RU2339621C2 (ru) 2008-11-27
AR103508A2 (es) 2017-05-17
MY141871A (en) 2010-07-16
DE602004030553D1 (de) 2011-01-27
US20060189653A1 (en) 2006-08-24
IS2800B (is) 2012-09-15
ECSP056059A (es) 2006-01-27
BRPI0409154B1 (pt) 2014-03-25
AR043825A1 (es) 2005-08-17
CA2520990A1 (en) 2004-10-14
EP1613599A1 (en) 2006-01-11
TW200504025A (en) 2005-02-01
MXPA05010616A (es) 2005-11-23
CA2520990C (en) 2011-08-09
MA27761A1 (fr) 2006-02-01
US7605267B2 (en) 2009-10-20
NO20055099L (no) 2006-01-02
ES2358193T3 (es) 2011-05-06
EP1613599B8 (en) 2011-06-22
DK1613599T3 (da) 2011-03-28
SI1613599T1 (sl) 2011-04-29
IS8095A (is) 2005-10-27
EP1613599B1 (en) 2010-12-15
HK1086833A1 (en) 2006-09-29
NZ542623A (en) 2008-07-31
PL1613599T3 (pl) 2011-05-31
AU2004226212B2 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
HRP20110184T1 (hr) Postupak priprave 5-(haloacetil)-8-(supstituirani oksi)-(1h)-kinolin-2-ona
US10047282B2 (en) Encrypted optical markers for security applications
US20100081688A1 (en) Process for the preparation of montelukast, and intermediates therefor
CN104098528A (zh) 铜催化二硫化碳合成2-巯基苯并噻唑类衍生物的方法
CN113233974A (zh) 一种酰基氟化物的合成方法
JP2006522055A5 (hr)
CN101139308A (zh) 杀菌剂中间体(e)-2-(2′-氯甲基)苯基-2-甲氧亚胺基乙酸甲酯的制备方法
JP2016503812A5 (hr)
TWI751203B (zh) 製備經環丙基取代之苯乙酮的方法
GB1237059A (en) Anti-virally effective quinoline derivatives
JP3765946B2 (ja) エポキシ樹脂組成物
JPS56104890A (en) Preparation of organosilane
PL111162B1 (en) Method of producing s-triethylophosphinogold 2,3,4,6-tetra-o-acetylo-beta-d-glycopyranosylothiol-1-ane
WO2005063661A1 (ja) フッ素化剤およびそれを用いる含フッ素化合物の製造方法
TH2103000895C3 (th) อนุพันธ์ของสาร 5,7-ไดไฮดรอกซี-3-เมทอกซี ฟลาโวน (5,7-dihydroxy-3-methoxy flavone)
CN109574902A (zh) 一种西洛多辛中间体的制备方法
US5093515A (en) Fluorinated benzoyl compounds
HU187355B (en) Process for preparing 2-amino-4-hydroxy-5-halo-substituted pyrimidine derivatives
Dua et al. 2, 3, 5, 6-TETRACHLORO-4-PYRIDYLCOPPER AND SOME DERIVATIVES
US4278814A (en) Preparation of 2-methylene-1,3-propanediamide by a fluoride anion-initiated β-elimination reaction
Györi et al. Bromo derivatives of amine and phosphine complexes of cyanodihydroborane. Synthesis and reactivity
KR100372563B1 (ko) 퀴놀론계항생제중간체인베타-케토에스테르유도체의제조방법
JPH04221328A (ja) 沃素化9,9−ジアルキルフルオレンの製造方法
CN108148032A (zh) 一种3,4-二氢-2h-1-苯并吡喃-2-羧酸类化合物的制备方法及其应用
EP0001290B1 (en) Substituted 2,3-dihydrobenz-(d)-isothiazole-1,1-dioxides and 2,3-dihydronaphtho-(1,8-de)-1,2-thiazine-1,1-dioxides